Liphorus Pharmaceuticals was founded in 2013 on the basis of Dr. Nabil G. Seidah's major discoveries at the IRCM, including the identification of the PCSK9 gene in 2002 and the development of an innovative approach to the treatment of hypercholesterolemia. Unlike injectable monoclonal antibodies that target circulating PCSK9, the technology developed at the IRCM acts within the cells themselves, paving the way for more accessible oral treatments that are likely to improve therapeutic adherence. In 2014, Liphorus successfully raised $6.4 million USD in Series A financing, solidifying its position on the international biotechnology scene.
